TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma
An erratum to this article was published (J Clin Endocrinol Metab, 16 Sep 2024 ↗)
Authors' conclusion
These results provide evidence that the TERT-p mutations alter the expression of different TERT splice variants, which, in turn, associates with different tumor aggressiveness.
Study context
- Population
- Papillary Thyroid Carcinomas (PTCs) operated on between November 2001 and March 2020 at Nagasaki University Hospital and Kuma Hospital
- Participants
- 207 PTCs
- Comparison
- Telomerase reverse transcriptase promoter (TERT-p) mutation and expression status groups
- Mut-/exp+n = 24
- Mut+/exp+n = 33
- Outcome
- TERT splice variants (α deletion, β deletion) by TERT-p status and clinicopathological features
Methodological detailstwo-centre, in vitro functional study
- Two-centre
- In vitro functional study
Main finding
As reported in the abstract
- +A+B expression was associated with higher PTC aggressiveness, whereas dB expression counteracted this effect
- In vitro, dB strongly inhibited cell growth, migration and clonogenicity, suggesting a tumor-suppressive role
- Mut+/exp+ vs mut-/exp+: significantly higher in mut+/exp+
Original publication
TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. Published 5 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →